Biogen stock

x2 1 day ago · Biogen currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is Vertex Pharmaceuticals VRTX , which presently flaunts a Zacks Rank #2 (Buy). Get Biogen Inc (BIIB:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.Biogen Idec Inc. NASDAQ Updated Mar 29, 2022 10:14 PM BIIB 214.95 3.27 (1.55%). Post-Market 0.00 (0.00%)Nov 26, 2021 · Biogen Inc. tumbled on Friday as setbacks for its Alzheimer’s disease drug Aduhelm helped erase all the gains the stock had made in 2021. The biotech stock has plunged more than 40% after ... Find the latest Biogen Inc. (BIIB) stock quote, history, news and other vital information to help you with your stock trading and investing. Mar 29, 2022 · Biogen Inc. (NASDAQ: BIIB) is a company that's managed strong profitability with its Roche collaboration in oncology and Biogen's MS business - its assets easily support a large swath of the business. BIIB: Get the latest Biogen stock price and detailed information including BIIB news, historical charts and realtime prices.Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know Biogen Inc. (BIIB) closed at $193.77 in the latest trading session, marking a -1.97% move from the prior day. Advertisement...Mar 29, 2022 · Biogen Inc. (NASDAQ: BIIB) is a company that's managed strong profitability with its Roche collaboration in oncology and Biogen's MS business - its assets easily support a large swath of the business. The Investor Relations website contains information about Biogen's business for stockholders, potential investors, and financial analysts.2 days ago · Shares of Biogen stock skyrocketed by over $100 per share on June 7, 2021. However, over the next six months, investors learned that Aduhelm would not be the blockbuster drug to conquer Alzheimer's or replace Biogen's MS drug line-up because the drug was dangerous and ineffective, hospital networks refused to prescribe it, and major insurance ... Biogen's shares traded at over $289 per share, and its market capitalization was valued at over US$63 billion in November 2018. The company ranked 228 on the 2021 Fortune 500 list of the largest United States corporations by revenue. Products PipelineMar 30, 2022 · Biogen has filed the final design for the required post-approval study of Aduhelm, its Alzheimer’s disease drug, with the Food and Drug Administration, the company said Wednesday. The FDA ... Biogen Inc. Analyst Report: Biogen Inc. Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and...Biogen Pharmach Share Price, Biogen Pharmach Stock Price, Biogen Pharmachem Industries Ltd. Stock Price, Share Price, Live BSE/NSE, Biogen Pharmachem Industries Ltd. Bids Offers. Buy/Sell Biogen...Biogen Idec Inc. NASDAQ Updated Mar 29, 2022 10:14 PM BIIB 214.95 3.27 (1.55%). Post-Market 0.00 (0.00%)BIIB: Get the latest Biogen stock price and detailed information including BIIB news, historical charts and realtime prices.Biogen currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is Vertex Pharmaceuticals VRTX , which presently flaunts a Zacks Rank #2 (Buy).Shares of Biogen stock skyrocketed by over $100 per share on June 7, 2021. However, over the next six months, investors learned that Aduhelm would not be the blockbuster drug to conquer Alzheimer's or replace Biogen's MS drug line-up because the drug was dangerous and ineffective, hospital networks refused to prescribe it, and major ...Shares of Biogen stock skyrocketed by over $100 per share on June 7, 2021. However, over the next six months, investors learned that Aduhelm would not be the blockbuster drug to conquer Alzheimer's or replace Biogen's MS drug line-up because the drug was dangerous and ineffective, hospital networks refused to prescribe it, and major ... The stock price of Biogen (NASDAQ:BIIB) has seen a 10% drop over the last five trading days. BIIB stock has seen a massive rally from levels of $267 in early June to around $380 last week, before...2 days ago · Shares of Biogen stock skyrocketed by over $100 per share on June 7, 2021. However, over the next six months, investors learned that Aduhelm would not be the blockbuster drug to conquer Alzheimer's or replace Biogen's MS drug line-up because the drug was dangerous and ineffective, hospital networks refused to prescribe it, and major insurance ... According to the issued ratings of 32 analysts in the last year, the consensus rating for Biogen stock is Hold based on the current 17 hold ratings and 15 buy ratings for BIIB. The average twelve-month price target for Biogen is $281.16 with a high price target of $500.00 and a low price target of $185.00. Learn more on BIIB's analyst rating ...A high-level overview of Biogen Inc. (BIIB) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Mar 29, 2022 · Biogen Inc. (NASDAQ: BIIB) is a company that's managed strong profitability with its Roche collaboration in oncology and Biogen's MS business - its assets easily support a large swath of the business. The stock price of Biogen (NASDAQ:BIIB) has seen a 10% drop over the last five trading days. BIIB stock has seen a massive rally from levels of $267 in early June to around $380 last week, before...Find real-time BIIB - Biogen Inc stock quotes, company profile, news and forecasts from CNN Business.Shares of Biogen stock skyrocketed by over $100 per share on June 7, 2021. However, over the next six months, investors learned that Aduhelm would not be the blockbuster drug to conquer Alzheimer's or replace Biogen's MS drug line-up because the drug was dangerous and ineffective, hospital networks refused to prescribe it, and major ...Biogen Stock Forecast, Price & News $210.92 +4.11 (+1.99%) (As of 03/22/2022 04:00 PM ET) Today's Range $206.00 $212.11 50-Day Range $193.77 $239.30 52-Week Range $192.67 $468.55 Volume 849,649 shs Average Volume 1.45 million shs Market Capitalization $31.00 billion P/E Ratio 20.28 Dividend Yield N/A Beta 0.45 Profile Analyst Ratings ChartBiogen 2022 profit forecast misses estimates on Aduhelm woes Reuters • 1 day ago See All News Data is currently not available About Key Executives Name Title Trending Stocks FB Meta Platforms, Inc....Biogen Stock Forecast, Price & News $210.92 +4.11 (+1.99%) (As of 03/22/2022 04:00 PM ET) Today's Range $206.00 $212.11 50-Day Range $193.77 $239.30 52-Week Range $192.67 $468.55 Volume 849,649 shs Average Volume 1.45 million shs Market Capitalization $31.00 billion P/E Ratio 20.28 Dividend Yield N/A Beta 0.45 Profile Analyst Ratings ChartMar 28, 2022 · CAMBRIDGE, Mass. and CARLSBAD, Calif., March 28, 2022 /PRNewswire/ -- Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced topline results from the Phase 1 ... Biogen Inc. Analyst Report: Biogen Inc. Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and... Analyst Forecast. According to 42 analysts, the average rating for BIIB stock is "Buy." The 12-month stock price forecast is 257.68, which is an increase of 20.97% from the latest price.2 days ago · Shares of Biogen stock skyrocketed by over $100 per share on June 7, 2021. However, over the next six months, investors learned that Aduhelm would not be the blockbuster drug to conquer Alzheimer's or replace Biogen's MS drug line-up because the drug was dangerous and ineffective, hospital networks refused to prescribe it, and major insurance ... Mar 29, 2022 · Biogen Inc. (NASDAQ: BIIB) is a company that's managed strong profitability with its Roche collaboration in oncology and Biogen's MS business - its assets easily support a large swath of the business. 2 days ago · Shares of Biogen stock skyrocketed by over $100 per share on June 7, 2021. However, over the next six months, investors learned that Aduhelm would not be the blockbuster drug to conquer Alzheimer’s or replace Biogen’s MS drug line-up because the drug was dangerous and ineffective, hospital networks refused to prescribe it, and major ... Mar 28, 2022 · CAMBRIDGE, Mass. and CARLSBAD, Calif., March 28, 2022 /PRNewswire/ -- Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced topline results from the Phase 1 ... 2 days ago · Shares of Biogen stock skyrocketed by over $100 per share on June 7, 2021. However, over the next six months, investors learned that Aduhelm would not be the blockbuster drug to conquer Alzheimer’s or replace Biogen’s MS drug line-up because the drug was dangerous and ineffective, hospital networks refused to prescribe it, and major ... The latest closing stock price for Biogen as of March 18, 2022 is 208.57. The all-time high Biogen stock closing price was 475.98 on March 20, 2015. The Biogen 52-week high stock price is 468.55, which is 124.6% above the current share price. The Biogen 52-week low stock price is 192.67, which is 7.6% below the current share price.Biogen's Alzheimer's Drug Has Another Shot at Success Key Stock Data P/E Ratio (TTM) 20.17 (03/23/22) EPS (TTM) $10.39 Market Cap $31.00 B Shares Outstanding 146.96 M Public Float 146.41 M Yield...Mar 28, 2022 · CAMBRIDGE, Mass. and CARLSBAD, Calif., March 28, 2022 /PRNewswire/ -- Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced topline results from the Phase 1 ... Find the latest Biogen Inc. (BIIB) stock quote, history, news and other vital information to help you with your stock trading and investing. 2 days ago · Shares of Biogen stock skyrocketed by over $100 per share on June 7, 2021. However, over the next six months, investors learned that Aduhelm would not be the blockbuster drug to conquer Alzheimer’s or replace Biogen’s MS drug line-up because the drug was dangerous and ineffective, hospital networks refused to prescribe it, and major ... Mar 28, 2022 · CAMBRIDGE, Mass. and CARLSBAD, Calif., March 28, 2022 /PRNewswire/ -- Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced topline results from the Phase 1 ... Shares of Biogen stock skyrocketed by over $100 per share on June 7, 2021. However, over the next six months, investors learned that Aduhelm would not be the blockbuster drug to conquer Alzheimer's or replace Biogen's MS drug line-up because the drug was dangerous and ineffective, hospital networks refused to prescribe it, and major insurance ...BIIB: Get the latest Biogen stock price and detailed information including BIIB news, historical charts and realtime prices.View the latest BIIB stock quote and chart on MSN Money. Dive deeper with interactive charts and top stories of BIOGEN INC..Jun 24, 2012 · A high-level overview of Biogen Inc. (BIIB) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Biogen has filed the final design for the required post-approval study of Aduhelm, its Alzheimer's disease drug, with the Food and Drug Administration, the company said Wednesday. The FDA ...Over the past 20 years this proprietary AI has been refined to help identify the most opportune trading strategies for both individual stocks and the stock markets themselves. This methodology is also applied to Index options, ETFs, and futures.Biotech heavyweight Biogen ( BIIB -1.83% ) is poised for a sizable jump in its share price later today once the trading halt on its stock is lifted following the surprise Food and Drug...BIIB: Get the latest Biogen stock price and detailed information including BIIB news, historical charts and realtime prices.Analyst Forecast. According to 42 analysts, the average rating for BIIB stock is "Buy." The 12-month stock price forecast is 257.68, which is an increase of 20.97% from the latest price.Over the past 20 years this proprietary AI has been refined to help identify the most opportune trading strategies for both individual stocks and the stock markets themselves. This methodology is also applied to Index options, ETFs, and futures.Mar 28, 2022 · CAMBRIDGE, Mass. and CARLSBAD, Calif., March 28, 2022 /PRNewswire/ -- Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced topline results from the Phase 1 ... 1 day ago · Shares of BIIB stock traded up $0.38 during mid-day trading on Monday, hitting $211.41. 1,263 shares of the stock traded hands, compared to its average volume of 1,383,427. The firm has a market ... Jun 24, 2012 · A high-level overview of Biogen Inc. (BIIB) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Analyst Forecast. According to 42 analysts, the average rating for BIIB stock is "Buy." The 12-month stock price forecast is 257.68, which is an increase of 20.97% from the latest price.View the latest BIIB stock quote and chart on MSN Money. Dive deeper with interactive charts and top stories of BIOGEN INC..2 days ago · Shares of Biogen stock skyrocketed by over $100 per share on June 7, 2021. However, over the next six months, investors learned that Aduhelm would not be the blockbuster drug to conquer Alzheimer's or replace Biogen's MS drug line-up because the drug was dangerous and ineffective, hospital networks refused to prescribe it, and major insurance ... Biogen has filed the final design for the required post-approval study of Aduhelm, its Alzheimer's disease drug, with the Food and Drug Administration, the company said Wednesday. The FDA ...Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know Biogen Inc. (BIIB) closed at $193.77 in the latest trading session, marking a -1.97% move from the prior day. Advertisement...Biogen Idec Inc. NASDAQ Updated Mar 29, 2022 10:14 PM BIIB 214.95 3.27 (1.55%). Post-Market 0.00 (0.00%)2 days ago · Shares of Biogen stock skyrocketed by over $100 per share on June 7, 2021. However, over the next six months, investors learned that Aduhelm would not be the blockbuster drug to conquer Alzheimer's or replace Biogen's MS drug line-up because the drug was dangerous and ineffective, hospital networks refused to prescribe it, and major insurance ... Find the latest Biogen Inc. (BIIB) stock quote, history, news and other vital information to help you with your stock trading and investing. Shares of Biogen stock skyrocketed by over $100 per share on June 7, 2021. However, over the next six months, investors learned that Aduhelm would not be the blockbuster drug to conquer Alzheimer's or replace Biogen's MS drug line-up because the drug was dangerous and ineffective, hospital networks refused to prescribe it, and major insurance ...2 days ago · Shares of Biogen stock skyrocketed by over $100 per share on June 7, 2021. However, over the next six months, investors learned that Aduhelm would not be the blockbuster drug to conquer Alzheimer's or replace Biogen's MS drug line-up because the drug was dangerous and ineffective, hospital networks refused to prescribe it, and major insurance ... Shares of Biogen stock skyrocketed by over $100 per share on June 7, 2021. However, over the next six months, investors learned that Aduhelm would not be the blockbuster drug to conquer Alzheimer's or replace Biogen's MS drug line-up because the drug was dangerous and ineffective, hospital networks refused to prescribe it, and major ...Biogen Pharmach Share Price, Biogen Pharmach Stock Price, Biogen Pharmachem Industries Ltd. Stock Price, Share Price, Live BSE/NSE, Biogen Pharmachem Industries Ltd. Bids Offers. Buy/Sell Biogen...2 days ago · Shares of Biogen stock skyrocketed by over $100 per share on June 7, 2021. However, over the next six months, investors learned that Aduhelm would not be the blockbuster drug to conquer Alzheimer's or replace Biogen's MS drug line-up because the drug was dangerous and ineffective, hospital networks refused to prescribe it, and major insurance ... Jun 24, 2012 · A high-level overview of Biogen Inc. (BIIB) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Biogen's Alzheimer's Drug Has Another Shot at Success Key Stock Data P/E Ratio (TTM) 20.17 (03/23/22) EPS (TTM) $10.39 Market Cap $31.00 B Shares Outstanding 146.96 M Public Float 146.41 M Yield...According to the issued ratings of 32 analysts in the last year, the consensus rating for Biogen stock is Hold based on the current 17 hold ratings and 15 buy ratings for BIIB. The average twelve-month price target for Biogen is $281.16 with a high price target of $500.00 and a low price target of $185.00. Learn more on BIIB's analyst rating ...The Investor Relations website contains information about Biogen's business for stockholders, potential investors, and financial analysts.Biogen Inc. Common Stock (BIIB) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Biogen has filed the final design for the required post-approval study of Aduhelm, its Alzheimer's disease drug, with the Food and Drug Administration, the company said Wednesday. The FDA ...Over the past 20 years this proprietary AI has been refined to help identify the most opportune trading strategies for both individual stocks and the stock markets themselves. This methodology is also applied to Index options, ETFs, and futures.Find the latest Biogen Inc. (BIIB) stock quote, history, news and other vital information to help you with your stock trading and investing. Biogen Inc. Analyst Report: Biogen Inc. Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and... Mar 30, 2022 · Biogen has filed the final design for the required post-approval study of Aduhelm, its Alzheimer’s disease drug, with the Food and Drug Administration, the company said Wednesday. The FDA ... Biogen's Alzheimer's Drug Has Another Shot at Success Key Stock Data P/E Ratio (TTM) 20.17 (03/23/22) EPS (TTM) $10.39 Market Cap $31.00 B Shares Outstanding 146.96 M Public Float 146.41 M Yield...BIIB: Get the latest Biogen stock price and detailed information including BIIB news, historical charts and realtime prices.1 day ago · Shares of BIIB stock traded up $0.38 during mid-day trading on Monday, hitting $211.41. 1,263 shares of the stock traded hands, compared to its average volume of 1,383,427. The firm has a market ... Nov 26, 2021 · Biogen Inc. tumbled on Friday as setbacks for its Alzheimer’s disease drug Aduhelm helped erase all the gains the stock had made in 2021. The biotech stock has plunged more than 40% after ... 1 day ago · Shares of BIIB stock traded up $0.38 during mid-day trading on Monday, hitting $211.41. 1,263 shares of the stock traded hands, compared to its average volume of 1,383,427. The firm has a market ... 1 day ago · Shares of BIIB stock traded up $0.38 during mid-day trading on Monday, hitting $211.41. 1,263 shares of the stock traded hands, compared to its average volume of 1,383,427. The firm has a market ... Jun 24, 2012 · A high-level overview of Biogen Inc. (BIIB) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Find real-time BIIB - Biogen Inc stock quotes, company profile, news and forecasts from CNN Business.2 days ago · Shares of Biogen stock skyrocketed by over $100 per share on June 7, 2021. However, over the next six months, investors learned that Aduhelm would not be the blockbuster drug to conquer Alzheimer’s or replace Biogen’s MS drug line-up because the drug was dangerous and ineffective, hospital networks refused to prescribe it, and major ... Over the past 20 years this proprietary AI has been refined to help identify the most opportune trading strategies for both individual stocks and the stock markets themselves. This methodology is also applied to Index options, ETFs, and futures.Biogen currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is Vertex Pharmaceuticals VRTX , which presently flaunts a Zacks Rank #2 (Buy).2 days ago · Shares of Biogen stock skyrocketed by over $100 per share on June 7, 2021. However, over the next six months, investors learned that Aduhelm would not be the blockbuster drug to conquer Alzheimer’s or replace Biogen’s MS drug line-up because the drug was dangerous and ineffective, hospital networks refused to prescribe it, and major ... Mar 29, 2022 · Biogen Inc. (NASDAQ: BIIB) is a company that's managed strong profitability with its Roche collaboration in oncology and Biogen's MS business - its assets easily support a large swath of the business. Biogen Inc. (NASDAQ: BIIB) is a company that's managed strong profitability with its Roche collaboration in oncology and Biogen's MS business - its assets easily support a large swath of the business.Biogen has filed the final design for the required post-approval study of Aduhelm, its Alzheimer's disease drug, with the Food and Drug Administration, the company said Wednesday. The FDA ...1 day ago · Shares of BIIB stock traded up $0.38 during mid-day trading on Monday, hitting $211.41. 1,263 shares of the stock traded hands, compared to its average volume of 1,383,427. The firm has a market ... (RTTNews) - Biogen Inc. (BIIB) said that it has submitted the final study protocol for the confirmatory envision trial of Alzheimer's disease drug, Aduhelm, to the U.S. Food and Drug ...The stock price of Biogen (NASDAQ:BIIB) has seen a 10% drop over the last five trading days. BIIB stock has seen a massive rally from levels of $267 in early June to around $380 last week, before...TradingView India. View live BIOGEN PHARMACHEM INDUSTRIES L chart to track its stock's price action. Find market predictions, BIOGEN financials and market news. Nov 26, 2021 · Biogen Inc. tumbled on Friday as setbacks for its Alzheimer’s disease drug Aduhelm helped erase all the gains the stock had made in 2021. The biotech stock has plunged more than 40% after ... The Investor Relations website contains information about Biogen's business for stockholders, potential investors, and financial analysts.Mar 28, 2022 · CAMBRIDGE, Mass. and CARLSBAD, Calif., March 28, 2022 /PRNewswire/ -- Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced topline results from the Phase 1 ... 2 days ago · Shares of Biogen stock skyrocketed by over $100 per share on June 7, 2021. However, over the next six months, investors learned that Aduhelm would not be the blockbuster drug to conquer Alzheimer's or replace Biogen's MS drug line-up because the drug was dangerous and ineffective, hospital networks refused to prescribe it, and major insurance ... 1 day ago · Shares of BIIB stock traded up $0.38 during mid-day trading on Monday, hitting $211.41. 1,263 shares of the stock traded hands, compared to its average volume of 1,383,427. The firm has a market ... According to the issued ratings of 32 analysts in the last year, the consensus rating for Biogen stock is Hold based on the current 17 hold ratings and 15 buy ratings for BIIB. The average twelve-month price target for Biogen is $281.16 with a high price target of $500.00 and a low price target of $185.00. Learn more on BIIB's analyst rating ...Biogen Idec Inc. NASDAQ Updated Mar 29, 2022 10:14 PM BIIB 214.95 3.27 (1.55%). Post-Market 0.00 (0.00%)Jun 24, 2012 · A high-level overview of Biogen Inc. (BIIB) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Mar 28, 2022 · CAMBRIDGE, Mass. and CARLSBAD, Calif., March 28, 2022 /PRNewswire/ -- Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced topline results from the Phase 1 ... 1 day ago · Shares of BIIB stock traded up $0.38 during mid-day trading on Monday, hitting $211.41. 1,263 shares of the stock traded hands, compared to its average volume of 1,383,427. The firm has a market ... Shares of Biogen stock skyrocketed by over $100 per share on June 7, 2021. However, over the next six months, investors learned that Aduhelm would not be the blockbuster drug to conquer Alzheimer's or replace Biogen's MS drug line-up because the drug was dangerous and ineffective, hospital networks refused to prescribe it, and major ...Biogen Idec Inc. NASDAQ Updated Mar 29, 2022 10:14 PM BIIB 214.95 3.27 (1.55%). Post-Market 0.00 (0.00%)Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know Biogen Inc. (BIIB) closed at $193.77 in the latest trading session, marking a -1.97% move from the prior day. Advertisement...The Investor Relations website contains information about Biogen's business for stockholders, potential investors, and financial analysts.The latest closing stock price for Biogen as of March 18, 2022 is 208.57. The all-time high Biogen stock closing price was 475.98 on March 20, 2015. The Biogen 52-week high stock price is 468.55, which is 124.6% above the current share price. The Biogen 52-week low stock price is 192.67, which is 7.6% below the current share price.Mar 29, 2022 · Biogen Inc. (NASDAQ: BIIB) is a company that's managed strong profitability with its Roche collaboration in oncology and Biogen's MS business - its assets easily support a large swath of the business. A high-level overview of Biogen Inc. (BIIB) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Find real-time BIIB - Biogen Inc stock quotes, company profile, news and forecasts from CNN Business.A high-level overview of Biogen Inc. (BIIB) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.2 days ago · Shares of Biogen stock skyrocketed by over $100 per share on June 7, 2021. However, over the next six months, investors learned that Aduhelm would not be the blockbuster drug to conquer Alzheimer's or replace Biogen's MS drug line-up because the drug was dangerous and ineffective, hospital networks refused to prescribe it, and major insurance ... 1 day ago · Biogen currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is Vertex Pharmaceuticals VRTX , which presently flaunts a Zacks Rank #2 (Buy). Biogen 2022 profit forecast misses estimates on Aduhelm woes Reuters • 1 day ago See All News Data is currently not available About Key Executives Name Title Trending Stocks FB Meta Platforms, Inc....The stock price of Biogen (NASDAQ:BIIB) has seen a 10% drop over the last five trading days. BIIB stock has seen a massive rally from levels of $267 in early June to around $380 last week, before...Mar 28, 2022 · 32 brokerages have issued 12 month price targets for Biogen's stock. Their forecasts range from $185.00 to $500.00. On average, they expect Biogen's share price to reach $281.16 in the next twelve months. This suggests a possible upside of 33.3% from the stock's current price. The latest closing stock price for Biogen as of March 18, 2022 is 208.57. The all-time high Biogen stock closing price was 475.98 on March 20, 2015. The Biogen 52-week high stock price is 468.55, which is 124.6% above the current share price. The Biogen 52-week low stock price is 192.67, which is 7.6% below the current share price.Biogen Pharmach Share Price, Biogen Pharmach Stock Price, Biogen Pharmachem Industries Ltd. Stock Price, Share Price, Live BSE/NSE, Biogen Pharmachem Industries Ltd. Bids Offers. Buy/Sell Biogen...Biogen's Alzheimer's Drug Has Another Shot at Success Key Stock Data P/E Ratio (TTM) 20.17 (03/23/22) EPS (TTM) $10.39 Market Cap $31.00 B Shares Outstanding 146.96 M Public Float 146.41 M Yield...2 days ago · Shares of Biogen stock skyrocketed by over $100 per share on June 7, 2021. However, over the next six months, investors learned that Aduhelm would not be the blockbuster drug to conquer Alzheimer's or replace Biogen's MS drug line-up because the drug was dangerous and ineffective, hospital networks refused to prescribe it, and major insurance ... 2 days ago · Shares of Biogen stock skyrocketed by over $100 per share on June 7, 2021. However, over the next six months, investors learned that Aduhelm would not be the blockbuster drug to conquer Alzheimer's or replace Biogen's MS drug line-up because the drug was dangerous and ineffective, hospital networks refused to prescribe it, and major insurance ... Mar 28, 2022 · 32 brokerages have issued 12 month price targets for Biogen's stock. Their forecasts range from $185.00 to $500.00. On average, they expect Biogen's share price to reach $281.16 in the next twelve months. This suggests a possible upside of 33.3% from the stock's current price. Shares of BIIB stock traded up $0.38 during mid-day trading on Monday, hitting $211.41. 1,263 shares of the stock traded hands, compared to its average volume of 1,383,427. The firm has a market ...1 day ago · Biogen currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is Vertex Pharmaceuticals VRTX , which presently flaunts a Zacks Rank #2 (Buy). Biogen Inc. (NASDAQ: BIIB) is a company that's managed strong profitability with its Roche collaboration in oncology and Biogen's MS business - its assets easily support a large swath of the business.Biogen Stock Forecast, Price & News $210.92 +4.11 (+1.99%) (As of 03/22/2022 04:00 PM ET) Today's Range $206.00 $212.11 50-Day Range $193.77 $239.30 52-Week Range $192.67 $468.55 Volume 849,649 shs Average Volume 1.45 million shs Market Capitalization $31.00 billion P/E Ratio 20.28 Dividend Yield N/A Beta 0.45 Profile Analyst Ratings ChartGet Biogen Inc (BIIB:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Biogen has filed the final design for the required post-approval study of Aduhelm, its Alzheimer's disease drug, with the Food and Drug Administration, the company said Wednesday. The FDA ...BIIB: Get the latest Biogen stock price and detailed information including BIIB news, historical charts and realtime prices.Over the past 20 years this proprietary AI has been refined to help identify the most opportune trading strategies for both individual stocks and the stock markets themselves. This methodology is also applied to Index options, ETFs, and futures.Jun 24, 2012 · A high-level overview of Biogen Inc. (BIIB) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Biogen is committed to the power of diversity - in our organization and among our patients and customers. Diversity is an essential asset of complementary strengths and perspectives from which all benefit, and which must unite us, not divide us. Learn more about our commitment.Biogen Stock Forecast, Price & News $210.92 +4.11 (+1.99%) (As of 03/22/2022 04:00 PM ET) Today's Range $206.00 $212.11 50-Day Range $193.77 $239.30 52-Week Range $192.67 $468.55 Volume 849,649 shs Average Volume 1.45 million shs Market Capitalization $31.00 billion P/E Ratio 20.28 Dividend Yield N/A Beta 0.45 Profile Analyst Ratings Chart1 day ago · Biogen currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is Vertex Pharmaceuticals VRTX , which presently flaunts a Zacks Rank #2 (Buy). 1 day ago · Shares of BIIB stock traded up $0.38 during mid-day trading on Monday, hitting $211.41. 1,263 shares of the stock traded hands, compared to its average volume of 1,383,427. The firm has a market ... TradingView India. View live BIOGEN PHARMACHEM INDUSTRIES L chart to track its stock's price action. Find market predictions, BIOGEN financials and market news. Shares of Biogen stock skyrocketed by over $100 per share on June 7, 2021. However, over the next six months, investors learned that Aduhelm would not be the blockbuster drug to conquer Alzheimer's or replace Biogen's MS drug line-up because the drug was dangerous and ineffective, hospital networks refused to prescribe it, and major ...Shares of BIIB stock traded up $0.38 during mid-day trading on Monday, hitting $211.41. 1,263 shares of the stock traded hands, compared to its average volume of 1,383,427. The firm has a market ...(RTTNews) - Biogen Inc. (BIIB) said that it has submitted the final study protocol for the confirmatory envision trial of Alzheimer's disease drug, Aduhelm, to the U.S. Food and Drug ...Mar 30, 2022 · Biogen has filed the final design for the required post-approval study of Aduhelm, its Alzheimer’s disease drug, with the Food and Drug Administration, the company said Wednesday. The FDA ... Biogen Pharmach Share Price, Biogen Pharmach Stock Price, Biogen Pharmachem Industries Ltd. Stock Price, Share Price, Live BSE/NSE, Biogen Pharmachem Industries Ltd. Bids Offers. Buy/Sell Biogen...The Investor Relations website contains information about Biogen's business for stockholders, potential investors, and financial analysts.(RTTNews) - Biogen Inc. (BIIB) said that it has submitted the final study protocol for the confirmatory envision trial of Alzheimer's disease drug, Aduhelm, to the U.S. Food and Drug ...Jun 24, 2012 · A high-level overview of Biogen Inc. (BIIB) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. BIIB: Get the latest Biogen stock price and detailed information including BIIB news, historical charts and realtime prices. Biogen’s Alzheimer’s Drug Has Another Shot at Success Key Stock Data P/E Ratio (TTM) 20.17 (03/23/22) EPS (TTM) $10.39 Market Cap $31.00 B Shares Outstanding 146.96 M Public Float 146.41 M Yield... Jun 24, 2012 · A high-level overview of Biogen Inc. (BIIB) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Biogen Idec Inc. NASDAQ Updated Mar 29, 2022 10:14 PM BIIB 214.95 3.27 (1.55%). Post-Market 0.00 (0.00%)Get Biogen Inc (BIIB:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.Mar 29, 2022 · Biogen Inc. (NASDAQ: BIIB) is a company that's managed strong profitability with its Roche collaboration in oncology and Biogen's MS business - its assets easily support a large swath of the business. View the latest BIIB stock quote and chart on MSN Money. Dive deeper with interactive charts and top stories of BIOGEN INC..Biogen has filed the final design for the required post-approval study of Aduhelm, its Alzheimer's disease drug, with the Food and Drug Administration, the company said Wednesday. The FDA ...Find the latest Biogen Inc. (BIIB) stock quote, history, news and other vital information to help you with your stock trading and investing. Biogen is committed to the power of diversity - in our organization and among our patients and customers. Diversity is an essential asset of complementary strengths and perspectives from which all benefit, and which must unite us, not divide us. Learn more about our commitment.Biotech heavyweight Biogen ( BIIB -1.83% ) is poised for a sizable jump in its share price later today once the trading halt on its stock is lifted following the surprise Food and Drug...Mar 29, 2022 · Biogen Inc. (NASDAQ: BIIB) is a company that's managed strong profitability with its Roche collaboration in oncology and Biogen's MS business - its assets easily support a large swath of the business. Over the past 20 years this proprietary AI has been refined to help identify the most opportune trading strategies for both individual stocks and the stock markets themselves. This methodology is also applied to Index options, ETFs, and futures.Mar 29, 2022 · Biogen Inc. (NASDAQ: BIIB) is a company that's managed strong profitability with its Roche collaboration in oncology and Biogen's MS business - its assets easily support a large swath of the business. Mar 28, 2022 · 32 brokerages have issued 12 month price targets for Biogen's stock. Their forecasts range from $185.00 to $500.00. On average, they expect Biogen's share price to reach $281.16 in the next twelve months. This suggests a possible upside of 33.3% from the stock's current price. Biogen is committed to the power of diversity - in our organization and among our patients and customers. Diversity is an essential asset of complementary strengths and perspectives from which all benefit, and which must unite us, not divide us. Learn more about our commitment.Mar 28, 2022 · CAMBRIDGE, Mass. and CARLSBAD, Calif., March 28, 2022 /PRNewswire/ -- Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced topline results from the Phase 1 ... Biogen is committed to the power of diversity - in our organization and among our patients and customers. Diversity is an essential asset of complementary strengths and perspectives from which all benefit, and which must unite us, not divide us. Learn more about our commitment.Biogen is committed to the power of diversity - in our organization and among our patients and customers. Diversity is an essential asset of complementary strengths and perspectives from which all benefit, and which must unite us, not divide us. Learn more about our commitment.BIIB: Get the latest Biogen stock price and detailed information including BIIB news, historical charts and realtime prices.Mar 28, 2022 · CAMBRIDGE, Mass. and CARLSBAD, Calif., March 28, 2022 /PRNewswire/ -- Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced topline results from the Phase 1 ... View the latest BIIB stock quote and chart on MSN Money. Dive deeper with interactive charts and top stories of BIOGEN INC..Jun 24, 2012 · A high-level overview of Biogen Inc. (BIIB) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know Biogen Inc. (BIIB) closed at $193.77 in the latest trading session, marking a -1.97% move from the prior day. Advertisement...Find real-time BIIB - Biogen Inc stock quotes, company profile, news and forecasts from CNN Business.Biogen has filed the final design for the required post-approval study of Aduhelm, its Alzheimer's disease drug, with the Food and Drug Administration, the company said Wednesday. The FDA ...Get Biogen Inc (BIIB:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.Biotech heavyweight Biogen ( BIIB -1.83% ) is poised for a sizable jump in its share price later today once the trading halt on its stock is lifted following the surprise Food and Drug...Find the latest Biogen Inc. (BIIB) stock quote, history, news and other vital information to help you with your stock trading and investing. Mar 28, 2022 · 32 brokerages have issued 12 month price targets for Biogen's stock. Their forecasts range from $185.00 to $500.00. On average, they expect Biogen's share price to reach $281.16 in the next twelve months. This suggests a possible upside of 33.3% from the stock's current price. Analyst Forecast. According to 42 analysts, the average rating for BIIB stock is "Buy." The 12-month stock price forecast is 257.68, which is an increase of 20.97% from the latest price.Biogen Idec Inc. NASDAQ Updated Mar 29, 2022 10:14 PM BIIB 214.95 3.27 (1.55%). Post-Market 0.00 (0.00%)Biogen is committed to the power of diversity - in our organization and among our patients and customers. Diversity is an essential asset of complementary strengths and perspectives from which all benefit, and which must unite us, not divide us. Learn more about our commitment.BIIB: Get the latest Biogen stock price and detailed information including BIIB news, historical charts and realtime prices.Mar 28, 2022 · CAMBRIDGE, Mass. and CARLSBAD, Calif., March 28, 2022 /PRNewswire/ -- Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced topline results from the Phase 1 ... View the latest BIIB stock quote and chart on MSN Money. Dive deeper with interactive charts and top stories of BIOGEN INC..Shares of Biogen stock skyrocketed by over $100 per share on June 7, 2021. However, over the next six months, investors learned that Aduhelm would not be the blockbuster drug to conquer Alzheimer's or replace Biogen's MS drug line-up because the drug was dangerous and ineffective, hospital networks refused to prescribe it, and major insurance ...2 days ago · Shares of Biogen stock skyrocketed by over $100 per share on June 7, 2021. However, over the next six months, investors learned that Aduhelm would not be the blockbuster drug to conquer Alzheimer's or replace Biogen's MS drug line-up because the drug was dangerous and ineffective, hospital networks refused to prescribe it, and major insurance ... Biogen Inc. (NASDAQ: BIIB) is a company that's managed strong profitability with its Roche collaboration in oncology and Biogen's MS business - its assets easily support a large swath of the business.Over the past 20 years this proprietary AI has been refined to help identify the most opportune trading strategies for both individual stocks and the stock markets themselves. This methodology is also applied to Index options, ETFs, and futures.Biogen Inc. (NASDAQ: BIIB) is a company that's managed strong profitability with its Roche collaboration in oncology and Biogen's MS business - its assets easily support a large swath of the business.Biogen Pharmach Share Price, Biogen Pharmach Stock Price, Biogen Pharmachem Industries Ltd. Stock Price, Share Price, Live BSE/NSE, Biogen Pharmachem Industries Ltd. Bids Offers. Buy/Sell Biogen...Mar 28, 2022 · CAMBRIDGE, Mass. and CARLSBAD, Calif., March 28, 2022 /PRNewswire/ -- Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced topline results from the Phase 1 ... Shares of Biogen stock skyrocketed by over $100 per share on June 7, 2021. However, over the next six months, investors learned that Aduhelm would not be the blockbuster drug to conquer Alzheimer's or replace Biogen's MS drug line-up because the drug was dangerous and ineffective, hospital networks refused to prescribe it, and major ...Biogen Pharmach Share Price, Biogen Pharmach Stock Price, Biogen Pharmachem Industries Ltd. Stock Price, Share Price, Live BSE/NSE, Biogen Pharmachem Industries Ltd. Bids Offers. Buy/Sell Biogen...1 day ago · Biogen currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is Vertex Pharmaceuticals VRTX , which presently flaunts a Zacks Rank #2 (Buy). Biotech heavyweight Biogen ( BIIB -1.83% ) is poised for a sizable jump in its share price later today once the trading halt on its stock is lifted following the surprise Food and Drug...According to the issued ratings of 32 analysts in the last year, the consensus rating for Biogen stock is Hold based on the current 17 hold ratings and 15 buy ratings for BIIB. The average twelve-month price target for Biogen is $281.16 with a high price target of $500.00 and a low price target of $185.00. Learn more on BIIB's analyst rating ...Mar 29, 2022 · Biogen Inc. (NASDAQ: BIIB) is a company that's managed strong profitability with its Roche collaboration in oncology and Biogen's MS business - its assets easily support a large swath of the business. Biogen Inc. (NASDAQ: BIIB) is a company that's managed strong profitability with its Roche collaboration in oncology and Biogen's MS business - its assets easily support a large swath of the business.TradingView India. View live BIOGEN PHARMACHEM INDUSTRIES L chart to track its stock's price action. Find market predictions, BIOGEN financials and market news. Mar 30, 2022 · Biogen has filed the final design for the required post-approval study of Aduhelm, its Alzheimer’s disease drug, with the Food and Drug Administration, the company said Wednesday. The FDA ... Mar 28, 2022 · 32 brokerages have issued 12 month price targets for Biogen's stock. Their forecasts range from $185.00 to $500.00. On average, they expect Biogen's share price to reach $281.16 in the next twelve months. This suggests a possible upside of 33.3% from the stock's current price. Jun 24, 2012 · A high-level overview of Biogen Inc. (BIIB) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Biogen has filed the final design for the required post-approval study of Aduhelm, its Alzheimer's disease drug, with the Food and Drug Administration, the company said Wednesday. The FDA ...A high-level overview of Biogen Inc. (BIIB) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.The Investor Relations website contains information about Biogen's business for stockholders, potential investors, and financial analysts.Biogen's Alzheimer's Drug Has Another Shot at Success Key Stock Data P/E Ratio (TTM) 20.17 (03/23/22) EPS (TTM) $10.39 Market Cap $31.00 B Shares Outstanding 146.96 M Public Float 146.41 M Yield...Mar 29, 2022 · Biogen Inc. (NASDAQ: BIIB) is a company that's managed strong profitability with its Roche collaboration in oncology and Biogen's MS business - its assets easily support a large swath of the business. Shares of Biogen stock skyrocketed by over $100 per share on June 7, 2021. However, over the next six months, investors learned that Aduhelm would not be the blockbuster drug to conquer Alzheimer's or replace Biogen's MS drug line-up because the drug was dangerous and ineffective, hospital networks refused to prescribe it, and major ...Over the past 20 years this proprietary AI has been refined to help identify the most opportune trading strategies for both individual stocks and the stock markets themselves. This methodology is also applied to Index options, ETFs, and futures.Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know Biogen Inc. (BIIB) closed at $193.77 in the latest trading session, marking a -1.97% move from the prior day. Advertisement...View the latest BIIB stock quote and chart on MSN Money. Dive deeper with interactive charts and top stories of BIOGEN INC..Mar 28, 2022 · CAMBRIDGE, Mass. and CARLSBAD, Calif., March 28, 2022 /PRNewswire/ -- Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced topline results from the Phase 1 ... Get Biogen Inc (BIIB:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.Mar 29, 2022 · Biogen Inc. (NASDAQ: BIIB) is a company that's managed strong profitability with its Roche collaboration in oncology and Biogen's MS business - its assets easily support a large swath of the business. Mar 29, 2022 · Biogen Inc. (NASDAQ: BIIB) is a company that's managed strong profitability with its Roche collaboration in oncology and Biogen's MS business - its assets easily support a large swath of the business. Mar 28, 2022 · 32 brokerages have issued 12 month price targets for Biogen's stock. Their forecasts range from $185.00 to $500.00. On average, they expect Biogen's share price to reach $281.16 in the next twelve months. This suggests a possible upside of 33.3% from the stock's current price. 2 days ago · Shares of Biogen stock skyrocketed by over $100 per share on June 7, 2021. However, over the next six months, investors learned that Aduhelm would not be the blockbuster drug to conquer Alzheimer's or replace Biogen's MS drug line-up because the drug was dangerous and ineffective, hospital networks refused to prescribe it, and major insurance ... Shares of Biogen stock skyrocketed by over $100 per share on June 7, 2021. However, over the next six months, investors learned that Aduhelm would not be the blockbuster drug to conquer Alzheimer's or replace Biogen's MS drug line-up because the drug was dangerous and ineffective, hospital networks refused to prescribe it, and major insurance ...Biogen Inc. Analyst Report: Biogen Inc. Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and...Biogen Idec Inc. NASDAQ Updated Mar 29, 2022 10:14 PM BIIB 214.95 3.27 (1.55%). Post-Market 0.00 (0.00%)Jun 24, 2012 · A high-level overview of Biogen Inc. (BIIB) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. (RTTNews) - Biogen Inc. (BIIB) said that it has submitted the final study protocol for the confirmatory envision trial of Alzheimer's disease drug, Aduhelm, to the U.S. Food and Drug ...Biogen Inc. Common Stock (BIIB) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Mar 30, 2022 · Biogen has filed the final design for the required post-approval study of Aduhelm, its Alzheimer’s disease drug, with the Food and Drug Administration, the company said Wednesday. The FDA ... 2 days ago · Shares of Biogen stock skyrocketed by over $100 per share on June 7, 2021. However, over the next six months, investors learned that Aduhelm would not be the blockbuster drug to conquer Alzheimer’s or replace Biogen’s MS drug line-up because the drug was dangerous and ineffective, hospital networks refused to prescribe it, and major ... Biogen currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is Vertex Pharmaceuticals VRTX , which presently flaunts a Zacks Rank #2 (Buy).BIIB: Get the latest Biogen stock price and detailed information including BIIB news, historical charts and realtime prices.Biotech heavyweight Biogen ( BIIB -1.83% ) is poised for a sizable jump in its share price later today once the trading halt on its stock is lifted following the surprise Food and Drug...BIIB: Get the latest Biogen stock price and detailed information including BIIB news, historical charts and realtime prices.2 days ago · Shares of Biogen stock skyrocketed by over $100 per share on June 7, 2021. However, over the next six months, investors learned that Aduhelm would not be the blockbuster drug to conquer Alzheimer’s or replace Biogen’s MS drug line-up because the drug was dangerous and ineffective, hospital networks refused to prescribe it, and major ... The latest closing stock price for Biogen as of March 18, 2022 is 208.57. The all-time high Biogen stock closing price was 475.98 on March 20, 2015. The Biogen 52-week high stock price is 468.55, which is 124.6% above the current share price. The Biogen 52-week low stock price is 192.67, which is 7.6% below the current share price.The stock price of Biogen (NASDAQ:BIIB) has seen a 10% drop over the last five trading days. BIIB stock has seen a massive rally from levels of $267 in early June to around $380 last week, before...Analyst Forecast. According to 42 analysts, the average rating for BIIB stock is "Buy." The 12-month stock price forecast is 257.68, which is an increase of 20.97% from the latest price.Mar 30, 2022 · Biogen has filed the final design for the required post-approval study of Aduhelm, its Alzheimer’s disease drug, with the Food and Drug Administration, the company said Wednesday. The FDA ... According to the issued ratings of 32 analysts in the last year, the consensus rating for Biogen stock is Hold based on the current 17 hold ratings and 15 buy ratings for BIIB. The average twelve-month price target for Biogen is $281.16 with a high price target of $500.00 and a low price target of $185.00. Learn more on BIIB's analyst rating ...Mar 29, 2022 · Biogen Inc. (NASDAQ: BIIB) is a company that's managed strong profitability with its Roche collaboration in oncology and Biogen's MS business - its assets easily support a large swath of the business.